Table 3 Pathological response to SBRT and the correlation between clinical response
Patient | Pre-LT SBRT | LT | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BCLC stage | Dose (Gy)/fraction number | Prescription isodose/maximum dose* | Radiological response | RILD | Milan criteria | Median time to LT (months) | Donor type | Pathologic AJCC 8th stage | Max. tumor size | PVTT | Tumor necrosis | Recurrence site | Status | |
1 | B | 42/5 | 75%/5600 cGy | SD | – | B → B | 1.6 | CLT | IIIA | 2.5 | Present | 30% | – | DOO |
2 | B | 60/5 | 72%/8333 cGy | PR | – | B → B | 34.3 | LDLT | II | 2.2 | – | 5% | Liver, carcinomatosis | DOD |
3 | B | 45/5 | 75%/6000 cGy | SD | – | B → B | 7.3 | LDLT | II | 2.5 | – | 100% | Liver | DOD |
4 | B | 40/5 | 70%/5714 cGy | SD | – | B → B | 5.8 | LDLT | II | 6 | – | 99% | – | NED |
5 | A | 50/5 | 80%/6250 cGy | PR | – | W → W | 17.0 | CLT | II | 2.5 | – | 100% | – | NED |
6 | C | 55/5 | 73%/7534 cGy | PR | – | B → B | 4.0 | LDLT | II | 3.5 | Present | 10% | Bilateral lung | DOD |
7a b | A B | 45/5 45/5 | 79%/5696 cGy 75%/6000 cGy | CR CR | – – | W → W W → B | 23.0 | LDLT | II | 1 | – | 5% | – | DOO |
8 | C | 35/5 | 72%/4861 cGy | CR | Nonclassic | B → W | 8.6 | CLT | IIIA | 6 | – | 90% | – | DOO |
9 | A | 40/4 | 79%/5063 cGy | PR | – | W → W | 62.4 | CLT | IIIB | 5.5 | Present | NA | – | DOO |
10a b | B 0 | 50/5 50/5 | 78%/6410 cGy 76%/6579 cGy | PR SD | – – | B → W W → W | 40.5 | CLT | IIIC | 3.5 | – | 95% | liver, lymph nodes, left adrenal gland, | DOD |
11 | C | 45/5 | 75%/6000 cGy | PR | – | B → B | 11.7 | LDLT | I | 6.5 | – | 30% | – | DOO |
12 | C | 47.5/5 | 72%/6690 cGy | SD | – | B → B | 2.1 | CLT | No viable tumor | – | – | – | – | NED |
13 | B | 28/5 | 76%/3683 cGy | SD | – | B → B | 6.2 | NA | NA | NA | NA | NA | Solitary lung | NED |
14 | D | 50/5 | 90%/5853 cGy | CR | – | W → W | 8.3 | CLT | IA | 1.5 | Present | NA | – | NED |